---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059824"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-05-13T12:09:13+00:00"
generated_at: "2026-05-13T12:11:22.504689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026

## Summary
- Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.
- Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.
- CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.
- CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.
- Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M).

## SEC filing metadata
- accession: 0001104659-26-059824
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-05-13T12:09:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/0001104659-26-059824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/tm2614312d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059824
- JSON: https://secwatch.observer/filing/0001104659-26-059824.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059824.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same
  - Result: reported results
  source text: Century Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/0001104659-26-059824-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.